PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1276932
PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1276932
Global exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market is expected to reach USD 13,385.56 million by 2030 from USD 7,675.00 million in 2022, growing at a CAGR of 7.2% during the forecast period from 2023 to 2030.
Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market, By Dignosis (Imaging Tests and Pancreatic Function Test), Treatment (Nutritional Management and Pancreatic Enzyme Replacement Therapy (PERT), and Others), Drugs Type (Branded and Generic), End User (Specialty Clinics, Hospitals, Diagnostic Center, Homecare, Research and Academic Institutes, and Others), Distribution Channel (Direct Tender, Retail Pharmacy, Third Party Distributors, and Others), Industry Trends and Forecast to 2030.
Driver
Increasing prevalence of exocrine pancreatic insufficiency (EPI) due to chronic pancreatitis and cystic fibrosis
Restraint
Stringent regulations to hamper the exocrine pancreatic insufficiency (EPI) therapeutic and diagnostic sector
Opportunity
Increasing prevalence of pancreatic disorders and associated conditions
EagleBio
AbbVie.
Digestive Care, Inc.
Nordmark Arzneimittel GmbH & Co.
Cilian AG
Alcresta Therapeutics, Inc.
ChiRhoClin
Bioserv Diagnostics
Laboratory Corporation of America
Organon group of companies
Metagenics LLC
Janssen
Nestle.
VIVUS LLC.
ScheBo Biotech AG
Abbott.